Research Article
To Measure or Not to Measure: Direct Oral Anticoagulant Laboratory Assay Monitoring in Clinical Practice
Table 1
Patient baseline characteristics.
| | | Overall N = 119 | Apixaban n = 62 | Rivaroxaban n = 57 |
| | Age, years: median (IQR) | 74 (27–102) | 78 (33–102) | 69 (27–91) | | <65 years | 37 (31) | 13 (21) | 24 (42) | | 65–74 years | 26 (22) | 11 (18) | 15 (26) | | ≥75 years | 56 (47) | 38 (61) | 18 (32) | | Sex | | | | | Male | 60 (50) | 31 (50) | 29 (51) | | Female | 59 (50) | 31 (50) | 28 (49) | | Body Mass index, kg/m2: median (IQR) | 26.8 (17–64) | 26.0 (17–49) | 26.9 (17–64) | | ≥35 | 16 (13) | 6 (10) | 10 (18) | | 30–34.9 | 18 (15) | 11 (18) | 7 (12) | | 25–29.9 | 43 (36) | 22 (35) | 21 (37) | | 18.5–24.9 | 33 (28) | 17 (27) | 16 (28) | | <18.5 | 4 (3) | 3 (5) | 1 (2) | | Unknown | 5 (4) | 3 (5) | 2 (3) | | Past medical history | | | | | Gastrointestinal bleed | 8 (7) | 7 (11) | 1 (2) | | Stroke/TIA | 28 (24) | 18 (29) | 10 (18) | | eGFR <60 mL/min | 33 (28) | 26 (42) | 7 (12) | | Diabetes | 27 (23) | 18 (29) | 9 (16) | | Indication for anticoagulant | | | | | Stroke prevention with atrial fibrillation | 49 (41) | 14 (12) | 35 (29) | | Acute PE | 28 (24) | 16 (28) | 12 (19) | | Chronic PE | 14 (12) | 12 (21) | 2 (3) | | Acute DVT | 31 (26) | 18 (32) | 13 (21) | | Chronic DVT | 24 (20) | 19 (33) | 5 (8) | | Other | 9 (8) | 4 (7) | 5 (8) |
|
|
